Positive-charge Tuned Gelatin Hydrogel-siSPARC Injectable for SiRNA Anti-scarring Therapy in Post Glaucoma Filtration Surgery

Overview

Journal Sci Rep

Specialty Science

Date 2021 Jan 15

PMID 33446775

Citations 10

Authors

Yong Yao Chun

Zhu Li Yap

Li Fong Seet

Hiok Hong Chan

Li Zhen Toh

Stephanie W L Chu

Ying Shi Lee

Tina T Wong

Timothy T Y Tan

Affiliations

Soon will be listed here.

Abstract

Small interfering RNA (siRNA) therapy is a promising epigenetic silencing strategy. However, its widespread adoption has been severely impeded by its ineffective delivery into the cellular environment. Here, a biocompatible injectable gelatin-based hydrogel with positive-charge tuned surface charge is presented as an effective platform for siRNA protection and delivery. We demonstrate a two-step synthesis of a gelatin-tyramine (Gtn-Tyr) hydrogel with simultaneous charge tunability and crosslinking ability. We discuss how different physiochemical properties of the hydrogel interact with siSPARC (siRNA for secreted protein, acidic and rich in cysteine), and study the positive-charge tuned gelatin hydrogel as an effective delivery platform for siSPARC in anti-fibrotic treatment. Through in vitro studies using mouse tenon fibroblasts, the positive-charge tuned Gtn-Tyr hydrogel shows sustained siSPARC cellular internalization and effective SPARC silencing with excellent biocompatibility. Similarly, the same hydrogel platform delivering siSPARC in an in vivo assessment employing a rabbit model shows an effective reduction in subconjunctival scarring in post glaucoma filtration surgery, and is non-cytotoxic compared to a commonly used anti-scarring agent, mitomycin-C. Overall, the current siRNA delivery strategy involving the positive-charge tuned gelatin hydrogel shows effective delivery of gene silencing siSPARC for anti-fibrotic treatment. The current charge tunable hydrogel delivery system is simple to fabricate and highly scalable. We believe this delivery platform has strong translational potential for effective siRNA delivery and epigenetic silencing therapy.

Citing Articles

Gelatin and lipidoid integrate to create to enhance siRNA delivery with low toxicity.

Gangula A, Suresh D, Babu A, Li Z, Upendran A, Kannan R Bioact Mater. 2024; 40:557-570.

PMID: 39539730 PMC: 11558258. DOI: 10.1016/j.bioactmat.2024.06.008.

Novel Biomaterials in Glaucoma Treatment.

Klezlova A, Bulir P, Klapstova A, Netukova M, Senkova K, Horakova J Biomedicines. 2024; 12(4).

PMID: 38672168 PMC: 11048501. DOI: 10.3390/biomedicines12040813.

Gel/hydrogel-based in situ biomaterial platforms for cancer postoperative treatment and recovery.

Feng Y, Zhang Z, Tang W, Dai Y Exploration (Beijing). 2023; 3(5):20220173.

PMID: 37933278 PMC: 10582614. DOI: 10.1002/EXP.20220173.

Breaking Barriers in Eye Treatment: Polymeric Nano-Based Drug-Delivery System for Anterior Segment Diseases and Glaucoma.

Wu K, Ashkar S, Jain S, Marchand M, Tran S Polymers (Basel). 2023; 15(6).

PMID: 36987154 PMC: 10054733. DOI: 10.3390/polym15061373.

Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery.

Shao C, Sinha N, Mohan R, Webel A Biomedicines. 2023; 11(3.

PMID: 36979636 PMC: 10045591. DOI: 10.3390/biomedicines11030657.

References

Kang S, Kim J, Ahn M, Kim J, Heo M, Min D . RNAi nanotherapy for fibrosis: highly durable knockdown of CTGF/CCN-2 using siRNA-DegradaBALL (LEM-S401) to treat skin fibrotic diseases. Nanoscale. 2020; 12(11):6385-6393. DOI: 10.1039/c9nr10305h. View

Su K, Wang C . Recent advances in the use of gelatin in biomedical research. Biotechnol Lett. 2015; 37(11):2139-45. DOI: 10.1007/s10529-015-1907-0. View

Brekken R, Sage E . SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 2000; 19(7):569-80. DOI: 10.1016/s0945-053x(00)00105-0. View

Abozeid S, Hathout R, Abou-Aisha K . Silencing of the metastasis-linked gene, AEG-1, using siRNA-loaded cholamine surface-modified gelatin nanoparticles in the breast carcinoma cell line MCF-7. Colloids Surf B Biointerfaces. 2016; 145:607-616. DOI: 10.1016/j.colsurfb.2016.05.066. View

Higginbotham E, Stevens R, Musch D, Karp K, Lichter P, Bergstrom T . Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology. 1996; 103(4):650-6. DOI: 10.1016/s0161-6420(96)30639-8. View

Teixeira L, Feijen J, van Blitterswijk C, Dijkstra P, Karperien M . Enzyme-catalyzed crosslinkable hydrogels: emerging strategies for tissue engineering. Biomaterials. 2011; 33(5):1281-90. DOI: 10.1016/j.biomaterials.2011.10.067. View

Seet L, Su R, Toh L, Wong T . In vitro analyses of the anti-fibrotic effect of SPARC silencing in human Tenon's fibroblasts: comparisons with mitomycin C. J Cell Mol Med. 2011; 16(6):1245-59. PMC: 3823078. DOI: 10.1111/j.1582-4934.2011.01400.x. View

Wong T, Mead A, Khaw P . Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2003; 44(3):1097-103. DOI: 10.1167/iovs.02-0366. View

Que J, Cao Q, Sui T, Du S, Kong D, Cao X . Effect of FK506 in reducing scar formation by inducing fibroblast apoptosis after sciatic nerve injury in rats. Cell Death Dis. 2013; 4:e526. PMC: 3613834. DOI: 10.1038/cddis.2013.56. View

10.

Seet L, Tong L, Su R, Wong T . Involvement of SPARC and MMP-3 in the pathogenesis of human pterygium. Invest Ophthalmol Vis Sci. 2012; 53(2):587-95. DOI: 10.1167/iovs.11-7941. View

11.

McMahon H, Boucrot E . Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2011; 12(8):517-33. DOI: 10.1038/nrm3151. View

12.

Rai P, Kotecha A, Kaltsos K, Ruddle J, Murdoch I, Bunce C . Changing trends in the incidence of bleb-related infection in trabeculectomy. Br J Ophthalmol. 2012; 96(7):971-5. DOI: 10.1136/bjophthalmol-2011-300926. View

13.

Wang L, Boulaire J, Chan P, Chung J, Kurisawa M . The role of stiffness of gelatin-hydroxyphenylpropionic acid hydrogels formed by enzyme-mediated crosslinking on the differentiation of human mesenchymal stem cell. Biomaterials. 2010; 31(33):8608-16. DOI: 10.1016/j.biomaterials.2010.07.075. View

14.

Shigeeda T, Tomidokoro A, Chen Y, Shirato S, Araie M . Long-term follow-up of initial trabeculectomy with mitomycin C for primary open-angle glaucoma in Japanese patients. J Glaucoma. 2006; 15(3):195-9. DOI: 10.1097/01.ijg.0000212202.57029.45. View

15.

Kapoor M, Burgess D, Patil S . Physicochemical characterization techniques for lipid based delivery systems for siRNA. Int J Pharm. 2011; 427(1):35-57. DOI: 10.1016/j.ijpharm.2011.09.032. View

16.

Ding W, Pu W, Jiang S, Ma Y, Liu Q, Wu W . Evaluation of the antifibrotic potency by knocking down SPARC, CCR2 and SMAD3. EBioMedicine. 2018; 38:238-247. PMC: 6306344. DOI: 10.1016/j.ebiom.2018.11.016. View

17.

Zhou X, Tan F, Reveille J, Wallis D, Milewicz D, Ahn C . Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum. 2002; 46(11):2990-9. DOI: 10.1002/art.10601. View

18.

Jampel H, Quigley H, Melia B, Friedman D, Barron Y . Risk factors for late-onset infection following glaucoma filtration surgery. Arch Ophthalmol. 2001; 119(7):1001-8. DOI: 10.1001/archopht.119.7.1001. View

19.

Frizell E, Liu S, ABraham A, Ozaki I, Eghbali M, Sage E . Expression of SPARC in normal and fibrotic livers. Hepatology. 1995; 21(3):847-54. View

20.

Seet L, Su R, Barathi V, Lee W, Poh R, Heng Y . SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery. PLoS One. 2010; 5(2):e9415. PMC: 2828474. DOI: 10.1371/journal.pone.0009415. View